Antibody Industry Trends

Antibody Industry Trends

The start of 2024 has seen leaps in deals for antibody therapeutics, especially ADCs (antibody-drug conjugates). This report aims to explore the events and trends of the biopharmaceutical industry in Q1. As of now, only two novel antibody drugs have been approved this year, but many more in regulatory review are expected to be fully approved.

Apr 07, 2024

Image credit: DOI: 10.1038/s41577-021-00542-xThe progress of COVID-19 therapies has seen remarkable strides, particularly in the development and application of antibody-based treatments. Early in the pandemic, the focus was on supportive care, but the rapid advancement in antibody therapies has sign

May 21, 2024
Read time: 3 mins

MAGMA-seq is an integrated technology for antibody wide mutational scanning. DOI:10.1038/s41467-024-48072-zThe use of bioinformatics and computational methods were of high interest in several papers published this past week. Protein language models, akin to natural language processing tools, p

May 15, 2024
Read time: 3 mins

DOI:10.1126/science.adg0564 B cells, or B lymphocytes, are a crucial component of the adaptive immune system andhumoral immunity. They originate from the bone marrow and mature in secondary lymphoid organs, such as the spleen and lymph nodes. The B ce

May 09, 2024
Read time: 3 mins

Antibody drugs for diabetes typically target specific molecules involved in the regulation of blood sugar levels or the immune response against insulin-producing cells, or specific hormones or receptors involved in glucose metabolism. For instance, teplizumab (Tzield), targets CD3 on T cells, thus deactivating immune cells which attack β-cells.

May 01, 2024
Read time: 5 mins

As we age, our innate and adaptive immune system undergoes various changes, typically characterized by decreased lymphopoiesis and adaptive immunity, and increased inflammation and myeloid pathologies. Immunosenescence (the gradual deterioration of the immune system associated with ageing), makes individuals more susceptible to infections, less responsive to vaccines, and prone to the development of chronic inflammatory conditions and autoimmune diseases.

Apr 30, 2024
Read time: 3 mins

Fc-mediated antibody effector functions play an important role in the humoral immune response and form a necessary link between innate and adaptive immunity. The constant (Fc) region is the tail portion of an antibody that interacts with other components of the immune system, such as immune cells and complement proteins. Well-known functions include opsonization, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement activation.

Apr 23, 2024
Read time: 2 mins

Bispecific antibody-drug conjugates (BsADCs) are a new class of therapeutic drugs being developed to fight cancer. They combine the dual targeting ability of bispecific antibodies with the cell-killing power of cytotoxic drugs. BsADCs are designed to deliver cytotoxic drugs directly to cancer cells, while minimizing damage to healthy cells. While they are still in development, several exciting advances have occurred recently.

Apr 16, 2024
Read time: 2 mins

Here at the AACR Annual Meeting 2024, there are over 7000 abstracts, 300 poster presentations, and 50 symposia all about cancer research. A few topics that are currently trending in the conference include cancer vaccines, AI for diagnostics, novel immunotherapies, and antibody-drug conjugates (ADCs) as a new modality.

Apr 11, 2024
Read time: 4 mins

The development and approval of novel antibody drugs represent a significant segment of pharmaceutical innovation, addressing a wide range of diseases from cancer to autoimmune disorders. Since the first monoclonal antibody (mAb) drug was approved in 1986, there has been explosive growth in this area. By 2021, the US FDA had approved its 100th mAb product, with mAbs now accounting for nearly a fifth of the agency’s new drug approvals each year.

Apr 02, 2024
Read time: 4 mins

This month heralded the release of groundbreaking news involving the monoclonal antibody tegoprubart, which facilitated the successful transplantation of a genetically edited pig kidney into a 62-year-old man grappling with end-stage kidney disease.

Apr 01, 2024
Read time: 6 mins

This week, exciting news came out that Eledon Pharmaceuticals’ tegoprubart was successfully used to aid the first-ever transplant of a genetically-edited pig kidney into a 62-year-old man with end-stage kidney disease. Tegoprubart is an investigational anti-CD40L antibody that has a high affinity for CD40 ligand. CD40L signaling plays an important role in adaptive and innate immune cell activation and function, and is therefore a target for non-lymphocyte depleting, immunomodulatory therapeutic intervention.

Mar 26, 2024
Read time: 3 mins

keep yourself updated with Biointron Insights

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.